Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001567619-19-013856
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-06-24 14:12:39
Reporting Period:
2019-06-20
Accepted Time:
2019-06-24 14:12:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1082038 Durect Corp DRRX Pharmaceutical Preparations (2834) 943297098
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1325447 First Eagle Investment Management, Llc 1345 Avenue Of The Americas
48Th Floor
New York NY 10105
No No Yes No
1457518 First Eagle Value In Biotechnology Master Fund, Ltd. Citco Trustees Limited (Cayman) Limited
89 Nexus Way, Camana Bay, Po Box 31106
Grand Cayman E9 KY1-1205
No No Yes No
1459688 21 April Fund, L.p. First Eagle Investment Management, Llc
1345 Avenue Of The Americas, 48Th Floor
New York NY 10105
No No Yes No
1459708 21 April Fund, Ltd. Citco Trustees (Cayman) Limited
89 Nexus Way, Camana Bay, Po Box 31106
Grand Cayman E9 KY1-1205
No No Yes No
1637141 First Eagle Holdings, Inc. 1345 Avenue Of The Americas
New York NY 10105
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-06-20 4,000,000 $0.52 26,476,546 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
Footnotes
  1. This Form 4 is filed by 21 April Fund, LP ("April LP"), 21 April Ltd. ("April Ltd."), First Eagle Investment Management, LLC ("FEIM"), First Eagle Value in Biotechnology Master Fund, Ltd. ("FEVIBM") and First Eagle Holdings, Inc. ("FEHI" and, collectively with April LP, April Ltd., FEIM and FEVIBM, the "Entities"). The Entities disclaim status as a "group" for purposes of this Form 4.
  2. Pursuant to a prospectus supplement, dated June 20, 2019, DURECT Corporation (the "Company") offered 29,000,000 shares of its common stock, par value $0.0001 per share (the "Common Stock") to certain investors of the Company. Pursuant to the terms that certain Securities Purchase Agreement, dated June 20, 2019, by and among the Company, April LP, April Ltd. and certain other persons, April LP and April Ltd purchased an aggregate of 4,000,000 shares of the Common Stock of the 29,000,000 made available in the offering at a price of $0.52 per share. The 4,000,000 shares of Common Stock represent 1,300,000 shares of Common Stock directly held by April LP and 2,700,000 shares of Common Stock directly held by April Ltd.
  3. Represents 4,726,893, 16,067,709, 5,586,944 and 95,000 shares of Common Stock held directly by 21 April LP, 21 April Ltd., FEVIBM and certain separately managed accounts, including accounts for which FEIM serves as registered investment adviser (the "Separately Managed Accounts"), respectively.
  4. The shares of Common Stock reported herein are indirectly beneficially owned by FEHI and FEIM, a Delaware limited liability company and an investment adviser registered under the Investment Advisers Act of 1940. FEIM is (i) a general partner of April LP, (ii) the registered investment adviser to FEVIBM as well as to April LP and April Ltd. (collectively, the "Funds"), (iii) a subsidiary of FEHI and (iv) the investment adviser to certain of the Separately Managed Accounts. FEHI disclaims beneficial ownership of the shares of Common Stock held directly by the Funds except to the extent, if any, of its pecuniary interest therein, and this report shall not be deemed an admission that FEHI is the beneficial owner of any such securities.